Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosing sale activity by a holder associated with SOPH. The filing lists restricted stock units (1 RSU) with an award date of 04/02/2026 and three 10b5-1 sale transactions totaling 5,707 shares executed on 03/19/2026, 04/06/2026, and 04/07/2026.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported routine share sales tied to equity compensation taxes. He sold a total of 5,100 Ordinary Shares in open-market transactions on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations arising from restricted stock unit vesting on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, rather than as discretionary trades. Following the sales, he directly holds 281,452 Ordinary Shares.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert sold 624 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 6, 2026 at prices around $4.86 per share and were executed solely to cover tax obligations from recently vested restricted stock units.
After these tax-related sales, Puylaert directly holds 148,230 Ordinary Shares, indicating that only a very small portion of his equity position was used for the "sell to cover" transactions, which the company describes as non-discretionary rather than voluntary market trades.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 5,105 Ordinary Shares of SOPH in early April 2026. The sales, at weighted average prices of about $4.86–$4.87 per share, were made in the open market to cover tax withholding obligations from recently vested restricted stock units.
According to the disclosure, these transactions on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After the sales, Van Well continues to hold more than 350,000 Ordinary Shares directly.
SOPHiA GENETICS SA president Ross Muken sold 5,024 Ordinary Shares in two small open-market transactions to cover taxes on recent equity vesting. On April 6 and 7, 2026, he sold 2,600 shares at a weighted average of $4.8474 and 2,424 shares at $4.8686.
The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1 trading plan and were not discretionary trades. After these sales, he continues to hold 698,097 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold a total of 5,100 Ordinary Shares of the company in early April 2026. The transactions were open‑market sales made solely to cover tax withholding obligations triggered by the vesting of restricted stock units on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan and were not discretionary trades. Camblong sold 2,600 shares on April 6 at a weighted average price of $4.8517 and 2,500 shares on April 7 at a weighted average price of $4.8619, and continued to hold about 3.73 million Ordinary Shares directly after these sales.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported small open-market sales of 4,933 Ordinary Shares to cover taxes on recent equity vesting. On April 6, he sold 2,520 shares at a weighted average price of $4.8456, followed by 2,413 shares on April 7 at a weighted average price of $4.8771. According to the disclosure, these trades were made under a pre-established Rule 10b5-1 trading plan and were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. After these transactions, he continues to hold 292,861 Ordinary Shares directly, indicating the sales represent a small, routine portion of his overall stake.
SOPHiA GENETICS SA Chief People Officer Manuela Valente reported open-market sales of company ordinary shares that were made to cover tax obligations from recent restricted stock unit vesting. The transactions, totaling 4,973 shares sold at prices around $4.85 per share, were executed under a pre-established Rule 10b5-1 trading plan.
Following these sales, Valente continues to hold 219,275 ordinary shares directly. Because the trades were specifically to satisfy tax withholding and were pre-planned, they reflect routine administration of equity compensation rather than discretionary buying or selling decisions.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open-market sales of ordinary shares tied to tax withholding on recently vested restricted stock units. The transactions covered a total of 5,100 shares at weighted average prices around $4.86 per share.
According to the disclosure, the sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades to satisfy tax obligations. Following these transactions, Xu directly holds 644,952 ordinary shares.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported open-market sales of a total of 3,549 Ordinary Shares to cover tax obligations from recently vested restricted stock units. The sales on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary.
After these transactions, Verma directly holds 204,400 Ordinary Shares.